Sanofi SNY announced preliminary data from the phase II TIDE-Asthma study, which evaluated its anti-OX40L mAb, amlitelimab, ...

Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

Sanofi and Regeneron's drug is already approved to treat atopic dermatitis and severe asthma in adults, and the green light in CRSwNP comes ... as its $36,000 list price is a huge premium on ...

With regard to the asthma indication, the GSK submission seeks approval for the drug in individuals aged 12 years and older. Concerning CRSwNP, GSK intends to secure approval in adults.

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...

as add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). The Prescription Drug User Fee Act (PDUFA) date is 16 December 2025.

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent ... a heavy social and economic burden. Results from a drug trial showed AstraZeneca and Amgen's new drug Tezspire ...